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Stem cell-derived cardiomyocytesRegenerating the human heart is a challenge that has engaged researchers and clinicians around the globe for
nearly a century. From the repair of theﬁrst septal defect in 1953, followed by theﬁrst successful heart transplant
in 1967, and later to the ﬁrst infusion of bone marrow-derived cells to the human myocardium in 2002, signiﬁ-
cant progress has been made in heart repair. However, chronic heart failure remains a leading pathological bur-
denworldwide.Whyhas regenerating the human heart been such a challenge, and how close arewe to achieving
clinically relevant regeneration? Exciting progress has been made to establish cell transplantation techniques in
recent years, and new preclinical studies in large animal models have shed light on the promises and challenges
that lie ahead. In this review, we will discuss the history of cell therapy approaches and provide an overview of
clinical trials using cell transplantation for heart regeneration. Focusing on the delivery of human stem cell-
derived cardiomyocytes, current experimental strategies in the ﬁeld will be discussed as well as their clinical
translation potential. Although the human heart has not been regenerated yet, decades of experimental progress
have guided us onto a promising path.
Summary: Previouswork in clinical cell therapy for heart repair using bonemarrowmononuclear cells, mesenchy-
mal stem cells, and cardiac-derived cells have overall demonstrated safety and modest efﬁcacy. Recent advance-
ments using human stem cell-derived cardiomyocytes have established them as a next generation cell type for
moving forward, however certain challenges must be overcome for this technique to be successful in the clinics.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Amyocardial infarction (MI) transforms healthy and contractile myo-
cardium into an akinetic, ﬁbrotic tissue, resulting in a heart that cannot
pumpblood at full capacity. As theheart is oneof the least regenerative or-
gans in the body, this often leads to the development of chronic heart fail-
ure— a diseasewith a 50% survival rate over 5 years [1]. Current treatment
options are limited and consist primarily of palliative drugs, organ replace-
ment by heart transplant (available to b0.1% of heart failure patients), or
mechanical assist devices (with complications related to infection, throm-
bosis, and power supply). While these available treatments have greatly
impacted the trajectory of patient health after an MI, ischemic heart dis-
ease remains the number one cause of death and disabilityworldwide [2].
In recent years, the ﬁeld of heart regeneration has emerged from a
far-fetched notion to the forefront of cardiac research. Heart regenera-
tion is an interdisciplinary ﬁeld with the goal of restoring functional
myocardium after cardiac injury [3]. Approaches to repair the injured
heart have beenwidespread and include cell transplantation, gene ther-
apy, stimulating innate repair pathways, direct cellular reprogramming,
cardiac tissue engineering, and biomaterial delivery. The mostiology, 850 Republican Street,
85; fax: +1-206-897-1540.
his is an open access article under the Cestablished strategy for heart repair has been the delivery of exogenous
cells. Nearly every cell type imaginable has been transplanted into the
damaged myocardium, from skeletal myoblasts to pluripotent stem
cells and their derivatives. It is an exciting but challenging time for phy-
sicians, scientists, and engineers in the ﬁeld — we now have over a de-
cade of experience in clinical trials contributing to heart regeneration
research, and there are several promising preclinical strategies emerg-
ing as contenders to our current clinical approaches.
In this review, we provide an overview of the clinical trial progres-
sion using cell therapy to regenerate the heart after ischemic injury
and discuss strengths and limitations of these trials. We will then dis-
cuss current experimental strategies designed to improve upon what
we have learned in these clinical trials, focusing on the advancements
in stem cell-derived cardiomyocyte transplantation and the clinical
translatability of this approach for heart repair.
2. Cell therapy clinical trials for heart repair
Approximately 1 billion cardiomyocytes are lost during anMI [3]. As
the adult human heart has an extremely limited regenerative capacity,
this damaged myocardial tissue is replaced by ﬁbrotic scar. There is in-
creasing evidence of the slow cardiomyocyte turnover rate during nor-
mal organ growth and development (reviewed in Ref. [4]), and
following myocardial injury [5], however, this turnover accounts for aC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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injury region undergo cell division while most DNA replication occurs
without cytokinesis as a hypertrophic response, and there is minimal
contribution from progenitor cells [5]. As a result, the innate generation
of de novo cardiomyocytes post-MI falls orders of magnitude short of
meaningful regeneration.
Exogenous cell transplantation aims to repair damagedmyocardial tis-
sue either by delivering cells that act via paracrine-mediated effects or by
providing de novo cardiomyocytes that directly contribute to force pro-
duction. Toward this goal, numerous clinical trials have been conducted
using cell types including skeletal myoblasts, bone marrow-derived he-
matopoietic cells, mesenchymal stem cells (MSCs, also known as marrow
stromal cells), adipose-derived cells, endothelial progenitor cells, and
cardiac-derived cells (CDCs) (reviewed in Refs. [6–9]). A schematic over-
view of the derivation, deliverymode, and proposedmechanism of action
for themajor groups of cell therapies is provided in Fig. 1. An ideal cell type
for replacing damagedmyocardial tissuewould have contractile and elec-
trophysiological properties, the ability to survive and integrate into an is-
chemic area, proliferation potential, and the ability to elicit a paracrine
effect to stimulate endogenous regeneration (e.g., vascularization;
discussed in detail in Refs. [9] and [10]). Despite the plethora of cell
types tested in clinical trials to date, nonehasmet all of these expectations.
The type of cell used for transplantation inherently places restrictions on
important variables that may affect the success of cell therapy, making it
difﬁcult todirectly compare results across trials. These include thedelivery
mode (intracoronary catheter, transendocardial catheter, or epicardial
catheter delivery compared to epicardial delivery in tissue patches), the
availability of autologous or allogenic cells, and the timing of cell delivery
dependent on the need for in vitro cell expansion (i.e., MSCs require ex-
tensive in vitro expansion, while unfractionated bone marrow cells may
be delivered the same day of isolation).
The ﬁeld hasmade tremendous progress in terms of establishing clin-
ical trial design, delivery techniques, and demonstrating safety; however,
the clinical beneﬁts have been modest at best. This indicates that there is
room for improvement on our cell source. The two major cell sources
used in the clinics thus far have been bonemarrow-derived cells and car-
diac explant-derived cells, which are discussed below.
2.1. Bone marrow-derived cells
Following closely behind the ﬁrst major wave of clinical trials in the
ﬁeld using skeletal myoblasts [11], bone marrow-derived cells paved
theway for intracoronary cell therapy in the heart, transitioning quickly
into the clinic despite the scarcity of published evidence supporting
their role in heart regeneration at the time [12,13].
2.1.1. Bone marrow-derived mononuclear cell derivatives
Most bone marrow-derived cell transplantation trials in the heart
have used an unfractionated subpopulation called bonemarrowmono-
nuclear cells (BMMNCs) (reviewed in Ref. [14]). Referring to BMMNCs
as a stem cell preparation is a misnomer because true stem cells com-
prise well below 0.1% of the total mononuclear cell population.
Unfractionated BMMNCs principally consist of a heterogeneous popula-
tion of hematopoietic cells including monocytes, committed myeloid
progenitor cells and lymphocytes, and a small population of hematopoi-
etic and mesenchymal stem cells [9,15].
Intracoronary transplantation of BMMNCs into patients with acute
MI was ﬁrst reported in 2002 [13], and while this trial has been
discredited for ethics violations, it was followed by a ﬂurry of more rig-
orously performed studies.Most of these early BMMNC studies enrolled
acute MI patients with ST-segment elevation and a baseline ejection
fraction of 40–50%, and they reported functional improvement after
treatment. One such studywas the BOOST trial [16] inwhich autologous
BMMNCs (characterized as b1% CD34+) were isolated from patients
and delivered by intracoronary infusion to the infarct-related artery
the same day. No serious adverse events were reported in eithergroup, and cardiacmagnetic resonance imaging (MRI) at 6months indi-
cated a signiﬁcant increase in left ventricular (LV) ejection fraction after
cell treatment (compared to placebo control), providing evidence that
intracoronary infusion of BMMNCs improves systolic function in acute
MI patients. In longer-term follow-up studies, however, the control
group showed a “catch-up” period of recovery, such that beneﬁts of
BMMNCs could no longer be demonstrated [17]. Results from the
REPAIR-AMI trial [18] further supported efﬁcacy for BMMNCs, reporting
a 5.5% increase in LVejection fraction at 4months after intracoronary in-
fusion of BMMNCs compared to a 3.0% improvement in controls. While
the results of this studywere hindered by the use of quantitative LV an-
giography to assess function as opposed to cardiac MRI, the enrollment
of over 200 patients made this the largest BMMNC trial at the time and
set the standard for expected systolic improvement, albeit a modest in-
crease, after cell therapy. The same group reported that functional im-
provement persists up to 5 years posttreatment in a subset of patients
whowere enrolled in the TOP-CARE-AMI trial [19–21], which compared
the beneﬁts of BMMNCs to those of autologous circulating progenitor
cells isolated from venous blood.
Despite these and other studies reporting functional improvement
after BMMNC treatment (reviewed in Ref. [22]), larger trials employing
greater degrees of randomization, placebo controls, and blinding con-
ducted in the years following have not replicated these results. The Car-
diovascular Cell Therapy Research Network (CCTRN) was designed to
facilitate cell-based therapies in the United States [23] and sponsored
the FOCUS-CCTRN trial [24], which was one of the ﬁrst trials to target
patients with chronic LV dysfunctionwho had not qualiﬁed for revascu-
larization therapy post-MI. Enrolled patients had a mean baseline ejec-
tion fraction of 30–32% andNewYork Heart Association (NYHA) class of
2 or 3, andwhile therewas no improvement in the primary endpoints of
LV end systolic volume or maximal oxygen consumption, there was a
small yet statistically signiﬁcant 1.4% improvement in LV ejection frac-
tion over baseline at 6 months. The CCTRN also sponsored the TIME
and LateTIME trials to assess the inﬂuence of BMMNC delivery timing
on LV function [25–27]. Each of these double-blinded and placebo-
controlled trials enrolled successfully reperfused MI patients and deliv-
ered 150×106 autologous BMMNCs by intracoronary perfusion either at
day 3 or 7 (TIME) or at 2–3weeks (LateTIME) afterMI. Neither studyde-
tected any functional beneﬁt by cardiacMRI at 6months after cell treat-
ment, regardless of delivery timing. Similar in cell dose and design, the
SWISS-AMI study [28] compared BMMNC delivery at days 5–7 to deliv-
ery at weeks 3–4 after post-MI reperfusion and again detected no im-
provement in LV ejection fraction at 4 months. Collectively, these
studies challenge the earlier reports of functional improvement, but
they differ in using a double-blinded study design and in targeting pa-
tients with signiﬁcantly worse baseline cardiac function (for example,
the median ejection fraction of SWISS-AMI patients was 37%). It seems
unlikely to us that this difference in baseline cardiac function underlies
the difference, however, because the REPAIR-AMI trial found that the pa-
tientswith theworst ejection fractions showed the greatest improvement
with treatment. Results are eagerly awaited from the 3000-patient enroll-
ment,multicenter Phase 3 trial (the BAMI trial), which is currently under-
way in Europe, as itwill help clear up someof the conﬂicting results in the
ﬁeld (clinical trial identiﬁer NCT01569178 [29]).
2.1.2. Mesenchymal stem cells
Numerous trials have been conducted using MSCs puriﬁed from
bone marrow, which are adult cells characterized for their osteogenic,
chondrogenic, and adipogenic differentiation potential [30,31]. Less
than 0.01% of the cells isolated from bone marrow are considered
MSCs [32,33], therefore obtaining clinically relevant cell numbers re-
quires ex vivo expansion.
The ﬁrst clinical trial investigating the intracoronary injection of
MSCs reported an improvement in LV ejection fraction and increased
myocardial perfusion 3months after treatment [33], echoing the results
reported using BMMNCs at the time. A few studies have directly
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Fig. 1. Cell transplantation techniques and proposedmechanisms of cell therapy for heart regeneration. (A) Cell transplantation afterMI. (1) Cardiac-derived cells (CDCs) are isolated from
either the atrial appendage or the septal wall, expanded in vitro, and transplanted via intracoronary catheter delivery. (2) Bonemarrowmononuclear cells (BMMNCs) andmesenchymal
stem cells (MSCs) are harvested from the bone marrow. BMMNCs may undergo puriﬁcation steps followed by transplantation via intracoronary catheter delivery or intramyocardial in-
jection,whileMSCs require in vitro expansion prior to transplantation,most commonly by intramyocardial injection. (3)Humancardiomyocytes are derived fromhumanpluripotent stem
cells (hPSCs) after in vitro expansion and directed cardiac differentiation. The proposed clinical delivery method for hPSC-cardiomyocytes (hPSC-CMs) is via transepicardial or
transendocardial catheter-based injection. (B) Proposed mechanism of action after cell transplantation. Bone marrow-derived cells and CDCs work primarily though paracrine signaling,
in which transplanted cells secrete paracrine factors to the surrounding infarcted myocardium. hPSC-cardiomyocytes act primarily though the direct electromechanical integration with
neighboring host cardiomyocytes. Paracrine factors may also be secreted by the hPSC-cardiomyocytes.
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the TAC-HFT trial [34]. In this study, chronic MI patients received a
transendocardial injection of BMMNCs (harvested the day of implant)
or MSCs (expanded 4–6 weeks in vitro prior to implantation). While
there was no difference between groups in the 1-year serious adverse
event rate or LV ejection fraction, patients receiving MSCs showed in-
creased regional function by strain analysis and an improvement in exer-
cise capacity. These studies used autologous MSCs; however, a limitation
of this approach is that autologous MSCs require a signiﬁcant expansion
period between the time of bone marrow aspiration and implantation.
The POSEIDON trial was designed to address this and to directly compare
the safety andefﬁcacy of autologousMSCs to allogeneicMSCs [35]. Chron-
ic MI patients received a dose of 20, 100, or 200 million autologous or al-
logeneic MSCs, injected into the myocardium via a transendocardial
catheter, and the study concluded that neither cell source stimulated a
signiﬁcant adverse immune response. Curiously, there was an inverse
dose response in terms of improved ejection fraction and reversed LV re-
modeling, with more improvement detected in the 20 million cell dose
than the 200 million cell dose.
Up until this point, studies focused their efforts on testing cells in
their native MSC state, but the C-CURE trial took a unique approach by
treating autologous MSCs with a cytokine cocktail prior to transplanta-
tion [36]. Guided by NOGA electromechanical mapping, these cytokine-
stimulated MSCs were transplanted transendocardially into chronic
heart failure patients an average of 1540 days post-MI. Cell-treated pa-
tients showed an absolute improvement of 7% in their ejection fraction
and enhanced exercise capacity, compared to no improvement in con-
trols. This is a surprisingly large treatment effect, given the long dura-
tion postinfarction in these patients. As previously reviewed [37],
most MSC studies have demonstrated that the cells die off within aweek or two posttransplantation with little direct cardiac differentia-
tion.Mechanismsof beneﬁt in this trial could not be determined, but an-
imal studies suggest it is likely a paracrine action.
2.1.3. Comments on bone marrow-derived cell therapy
Through the successful completion of numerous Phase I clinical tri-
als, bone marrow-derived cell therapies have established an important
feasibility and safety baseline for delivering cells into the myocardium
[14,38]. While there have been a few reports of signiﬁcant functional
improvement, for themost part these therapies have resulted in amod-
est reduction in scar size after infarction with little (at best) improve-
ment in systolic function. Because the majority of transplanted cells
die off within a fewweeks [39] and there is no solid evidence of cardio-
genic potential, all beneﬁts are believed to be paracrine mediated
(Fig. 1B) [3]. Therapies using BMMNCs andMSCs suggest that interven-
tion by cell therapy can change the trajectory of wound healing and the
inﬂammatory response after an infarction, but with no long-term im-
provement in global heart function or long-term engraftment, these
therapies are not truly regenerating the heart.
2.2. Cardiac-derived cells
The most recent addition to the clinical trials has been CDCs, which
are derived from myocardial biopsies and grown as explants in culture
to obtain an autologous CDC population. Studies in rodents have sup-
ported their potential to be a more effective cell source than BMMNCs
and MSCs [40], and CDCs were originally postulated to be progenitor
cells capable of forming new cardiomyocytes. However, most investiga-
tors now think that these cells, like bone marrow cells, show minimal
long-term engraftment or cardiac differentiation and instead work
136 K.A. Gerbin, C.E. Murry / Cardiovascular Pathology 24 (2015) 133–140principally through paracrine signaling pathways. The three leading tri-
als using CDCs to date are described below.
2.2.1. The SCIPIO Trial
The ﬁrst trial using CDCs focused on cells expressing the surface anti-
gen c-kit, whichwere ﬁrst isolated and characterized in the rat [41]. Sim-
ilar to bone marrow-derived cells, initial animal studies suggested that
c-kit+ cells gave rise to cardiomyocytes; however, lineage tracing studies
have determined that these cells show minimal long-term engraftment
and only extremely low rates of cardiac differentiation in the adult
heart [42–44]. The SCIPIO (cardiac stem cell infusion in patients with is-
chemic cardiomyopathy) trial enrolled 33 heart failure patients with
chronicMI (mean ejection fraction of 27.5% at baseline), who underwent
a right atrial appendage biopsy during coronary bypass surgery. This atri-
al tissue was used to isolate a putative cardiac progenitor cell that
expressed the surface antigen c-kit and was negative for hematopoietic
and cardiovascular lineagemarkers. After 4months of in vitro expansion,
0.5–1 million cells were injected via the coronary arteries perfusing the
ischemicmyocardium of 20 patients, while 13 patients remained as con-
trols. Analysis of heart function by 3D echocardiography or cardiac MRI
showed an 8.2% and a 12.3% improvement in LV ejection fraction at 4
and 12 months, respectively, and, somewhat surprisingly, a reduction
in infarct size in a subset of patients [45]. Readers should know, however,
that results from this study have been ﬂagged with an “expression of
concern” by the editors of the Lancet relating to an ongoing investigation
pertaining to data integrity as of this writing [46].
2.2.2. The CADUCEUS Trial
The next trial of CDCs involved “cardiosphere-derived cells”, a mesen-
chymal cell population obtained by explant culture of endomyocardial bi-
opsies, followed by transient growth as cellular spheroids [47].
Cardiosphere-derived cells are heterogeneous by surface markers but
are primarily CD105+/CD45−. In the Phase I CADUCEUS (cardiosphere-
derived autologous stem cells to reverse ventricular dysfunction) trial
[48,49], patients with a mean LV ejection fraction of 39% undergoing pri-
mary angioplasty 2–4 weeks after MI had a right ventricular biopsy re-
moved to expand autologous cells. After a 1- to 3-month expansion
period, 25 million cardiosphere-derived cells were delivered as an
intracoronary infusion into the infarct-related artery. Although the prima-
ry endpoint was safety, cardiacMRI at 6 and 12months after cell delivery
revealed a reduction in infarct size (identiﬁed as a reduced region of de-
layed gadolinium enhancement) and an increase in viable myocardium.
Although there was no signiﬁcant change in global ejection fraction,
cell-treated patients showed improved regional systolic wall thickening
thatwasmaintained from4months to 1 year after treatment. The authors
interpreted the increase in viable myocardium seen by MRI as regenera-
tion, but pathological hypertrophy of preexisting cardiomyocytes cannot
be ruled out as an alternate explanation. Although not statistically signif-
icant, cell-treated patients experiencedhigher levels of nonsustained ven-
tricular tachycardia and serious adverse events at the 1-year follow-up,
which will require closer evaluation in future trials.
2.2.3. The ALCADIA Trial
The ALCADIA (autologous human cardiac-derived stem cell to treat is-
chemic cardiomyopathy) trial is ongoing at the time of this review (clin-
ical trial identiﬁer NCT00981006) and takes a combined cell therapy and
controlled growth factor-release approach that was ﬁrst established in a
porcinemodel of chronicMI [50]. The trial enrolled advanced heart failure
patientswith LVejection fraction of 15–45% andNYHAclass of 3 or 4,with
primary endpoints of 1-year safety and secondary endpoints of assessing
functional improvement by echocardiography and MRI, NYHA class, and
exercise capacity at 6 months. At the time of coronary artery bypass
grafting, patients received a transepicardial injection of autologous
CD105+/CD90+ CDCs grown from an endocardial biopsy (0.5 million
cells per kilogram of patient body weight). Injection sites were subse-
quently covered with a biodegradable gelatin sheet that was loadedwith basic ﬁbroblast growth factor (bFGF) by incubation with bFGF
prior to implantation. Although there were only six patients enrolled
and no controls at the time, preliminary reports suggest an increase in
ejection fraction, a decrease in infarct size, and an increase in patient aer-
obic exercise capacity [51]. If successful in larger-enrollment trials, this
dual cell delivery and biomaterialsmethodmay promote a shift in clinical
approaches in the future toward the combined use of cell and drug deliv-
ery, and this is a progressive approach that deservesmore attention in the
preclinical and clinical setting. Of course, sorting the effects of the cells
from the growth factor delivery will require additional control groups
where one of the combined factors is omitted.
2.2.4. Comments on CDC therapy
Taken together, the achievementsmadewith CDCs support some ad-
vantages over previous bone marrow-derived cell therapies. The need
for ex vivo cell expansion of CDCs has provided insight to a later post-
MI delivery timeline, and it is promising that cell delivery intomature in-
farct scars 1–4months post-MI has resulted in detectable improvements
in clinical endpoints (primarily a reduction in infarct size). How such a
reduction in scar volume is achieved remains mysterious because scar
size is typically quite stable by 3 months post-MI. We speculate that
the cellsmay reactivate innate immunemechanisms, particularly related
to themacrophage. It is important to note that long-term cell retention is
almost nil with both CDCs and BMMNCs; thus, any beneﬁtsmust require
only the transient presence of the cell. Although double-blinded studies
with CDCs have been precluded by the need for myocardial biopsy,
such trials in bone marrow-derived cell therapy have demonstrated
the importance of using proper controls, and this will be necessary in
moving forward with larger-scale trials. Since some groups are now
moving toward allogeneic CDCs, it should be feasible to have placebo-
controlled trials and to test these cells in acute MI patients [52].
3. Pluripotent stem cell-derived cardiomyocyte delivery
Considering themodest beneﬁts fromheart regeneration clinical tri-
als to date, there has been some debate over cell source — is there a
more potent cell type to use for transplantation into the heart? De
novo cardiomyocytes meet many of the desired characteristics outlined
earlier, but ﬁnding a reliable cell source for cardiomyocytes was pre-
cluded until the last decade. Methods to derive cardiomyocytes from
human pluripotent stem cells (hPSCs) have progressed tremendously
since the ﬁrst report of mouse embryonic stem cell-cardiomyocyte der-
ivation [53], and there are now several efﬁcient protocols to achieve car-
diac differentiation that mimic developmental pathways (reviewed in
Ref. [54]). These differentiation advancements have brought hPSC-
cardiomyocytes to the forefront as a promising next-generation cell
source, and their transplantation into the heart has been studied exten-
sively in preclinical experiments. The leading strategy for cell delivery
has been the intramyocardial injection of dispersed cardiomyocytes,
which mirrors the delivery methods established in many cardiac-
derived and bone marrow-derived cell transplantation clinical trials.
Using this approach, various groups have demonstrated that hPSC-
cardiomyocytes engraft in the infarct region of numerous animal models
and result in an increase in cardiac function (reviewed in Ref. [55]).
In contrast to bone marrow derivatives and CDCs, human
cardiomyocytes give stable, long-term grafts in infarcted hearts [56]. In-
herent cell properties give transplanted cardiomyocytes the capability
to electrically integrate with the host tissue, which is a prerequisite for
synchronous contraction with the host myocardium. The ﬂuorescent cal-
cium reporter proteinGCaMP3 [57] has been auseful tool to study the gap
junction coupling between graft and host tissue, and geneticallymodiﬁed
human embryonic stem cell (hESC)-cardiomyocytes expressing GCaMP3
have been found to electrically integrate with ischemia/reperfusion in-
jured rat hearts (Gerbin et al., in revision) aswell as in cryoinjured guinea
pig hearts [58,59]. Unlike previous cell transplantation studies that are
paracrine driven, this electrical coupling indicates that the engrafted
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and are directly contributing to force generation (Fig. 1B). Indeed, im-
provements in systolic function have been reported in various injury
models after hPSC-cardiomyocyte transplantation [60–62].
Successful studies demonstrating long-term cardiomyocyte engraft-
ment and functional integration in rodents have motivated the transla-
tion of this approach into a nonhuman primate injury model [63]. Pig-
tailedmacaques (Macaca nemestrina) received an ischemia/reperfusion
injury by inﬂating a balloon catheter into the distal left anterior de-
scending coronary artery for 90 min followed by reperfusion. Two
weeks later, after initiating immunosuppression, 1 billion hESC-
derived cardiomyocytes were transplanted through transepicardial in-
jections into the infarcted myocardial wall. This study was the ﬁrst to
demonstrate large-scale myocardial remuscularization (Fig. 2A), and
large cardiomyocyte grafts were found in the infarct region 3 months
after transplantation. Engrafted human cardiomyocytes demonstrated
in vivo maturation from 14 days to 84 days, as indicated by an increase
in cell diameter, sarcomere alignment, and myoﬁbril content (Fig. 2B).
Grafts were perfused by the host vasculature, which was shown by
the presence of CD31+ endothelial cells in the GFP+ graft and further
supported by 3D rendered microcomputed tomography to visualize
vessels within the graft region (Fig. 2C and D). Furthermore, GCaMP3
ﬂuorescence imaging showed that engrafted cardiomyocyteswere elec-
tromechanically coupled to the host (Fig. 2E), as had been previously
demonstrated in rodents. A notable concern from these studies,however, was the detection of nonfatal ventricular arrhythmias in the
cardiomyocyte-engrafted hearts. These arrhythmias were not observed
inmice, rats, or guinea pigs [58], demonstrating the importance of using
relevant large animal models. The ventricular arrhythmias will need to
be managed for safe translation of human cardiomyocytes to the clinic.
4. Translating hPSC-cardiomyocyte delivery to the clinic
While preclinical therapies with hPSC-derived cardiomyocytes have
shown promise and are progressing quickly, questions regarding car-
diomyocyte engraftment, phenotype, and large-scale production must
be addressed in order to promote successful translation from bench to
bedside. Firstly, cell survival after transplantation is low regardless of
the cell type and injury model used. Despite the improved engraftment
after adopting ‘prosurvival’ cell treatments prior to implantation [60],
current methods are not sufﬁcient to achieve long-term high cell reten-
tion. The use of tissue engineering approaches such as the implantation
of cell sheets, epicardial patches, or cardiomyocytes delivered in bioma-
terials may help increase the engraftment rate (reviewed in Refs.
[64–66]), although the development of minimally invasive delivery
techniques will be important for clinical translation.
Secondly, the optimal maturation state of cardiomyocytes for trans-
plantation is not fully understood. Previous studies suggest that an inter-
mediary maturation state may be ideal: mature adult cardiomyocytes do
not survive transplantation [67]; immature hESC-cardiomyocytes have
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mesodermal cardiac progenitor cells do not outperform deﬁnitive
cardiomyocytes in terms of engraftment or efﬁcacy (Fernandes and
Chong et al., in press). Current in vitro approaches may mature
cardiomyocytes from the ‘early-fetal’ state typically achieved after differ-
entiation into a late-fetal or neonatal stage. While in vitro maturation to
an adult phenotype will be difﬁcult, as indicated above it also is undesir-
able for transplantation purposes (reviewed in Ref. [68]). Experiments
that directly compare the engraftment of aged hPSC-cardiomyocytes to
the current standard are needed, as well as studies designed to track im-
planted cells and characterize their maturation in vivo.
Lastly, one of the major hurdles for successful translation of hPSC-
cardiomyocytes into the clinic is developing an “off-the-shelf” cardiomyo-
cyte cell product: will these come from hESCs or from human-induced
pluripotent stem cells (hiPSCs)? The biggest advantage of using hiPSCs
is their ability to provide an autologous cell source, but unfortunately,
this is also one of the major limitations when it comes to clinical and ﬁ-
nancial feasibility. The process of obtaining patient-speciﬁc somatic
cells, reprogramming to induced pluripotent stem cells, differentiating
into cardiomyocytes (perhaps requiring individual protocol optimiza-
tion), and performing quality control would take over 4 months [9].
This precludes their use in an acute or subacute MI setting, and converse-
ly, we have shown that hPSC-derived cardiomyocytes have no beneﬁcial
effect on cardiac function when delivered into chronic MIs in rats and
guinea pigs [56,59]. An additional limitation of the autologous hiPSC ap-
proach is the cost. At present, there are very expensive quality control ex-
periments that are required before the release of a product derived from
pluripotent stem cells, and doing this for each patient is cost prohibitive
unless the regulatory path is changed. There is also an inherent risk of re-
sidual undifferentiated stem cells giving rise to teratoma formation, and
proper quality control measures must be taken tominimize this risk [69].
Most preclinicalmodels thus far have used hESC-cardiomyocytes, al-
though immunosuppression after an allogeneic hESC-cardiomyocyte
implantation is a potential downfall of the therapy. More research is
needed to elucidate proper immunosuppression strategies that address
the differential immunogenicity and rejection of autologous vs. allogen-
ic cells (reviewed in Ref. [70]). Research strategies to engineer HLA-
homozygous hESC subclones or “universal donor cells” that are HLA
class 1 negative will be useful in addressing this problem, and exciting
progress has beenmade on this front in recent preclinical work [71]. Re-
gardless of cell source, it remains unclear if this number of cells can be
mass produced for clinical use in a way that is ﬁnancially manageable
and biologically controlled. Cardiomyocyte production will need to be
scaled up signiﬁcantly tomeet the current demand, although the devel-
opment of methods to increase cardiomyocyte proliferation for in vitro
scale-up may help alleviate this concern.
5. Concluding thoughts
As theﬁeld of cell-based cardiac repair hasmatured, there has been a
natural shift from basic studies toward more clinical and translational
goals. Nevertheless, it is important to continue with studies focusing
on the underlying biology of heart regeneration; understanding the bi-
ological mechanisms of cardiac repair will be critical in the ﬁeld’s suc-
cess regardless of therapeutic approach used. Simply put, unless we
understand the mechanisms through which cell therapies work, there
is noway to rationally improve upon them. A promising alternative ap-
proach to heart regeneration is stimulating endogenous repair after in-
jury, which takes advantage of cues learned from regeneration
experiments in lower vertebrates and the discovery of the mammalian
regenerative window after birth (reviewed in Ref. [72]). Although this
approach is far from the clinic, exciting progress has beenmade to iden-
tify factors that promote cardiomyocyte dedifferentiation and prolifera-
tion after injury, including the overexpression of cyclins [73–75], FGF
and NRG signaling pathways [76,77], Notch signaling [78,79], and
microRNAs [80]. Lessons learned here will provide important insightto the cell therapy ﬁeld and may guide the development of dual gene
and cell delivery therapies.
There are multiple parameters to consider when working toward
clinically meaningful regeneration including functional recovery, atten-
uation ofﬁbrosis, preventing adverse remodeling, cardiomyocyte prolif-
eration (and subsequent increase in viable myocardium), and the
maturation of regenerated cardiomyocytes. Because an ideal therapy
would be suitable for patients with recent cardiac injury or with
established heart failure, preclinical studies will require careful evalua-
tion of how to translate beneﬁts to a more chronically affected patient
population. The approaches discussed in this review were limited to is-
chemic heart disease; however, the advancements in the ﬁeld will have
broad implications for other heart failure patients, such as those suffer-
ing from dilated cardiomyopathy, hypertrophic cardiomyopathy, or
congenital heart disease. Better understanding the biology governing
the heart’s response to injury and to regenerative cues will provide in-
sight to better direct gene therapy, drug delivery, and tissue engineering
approaches that target nonischemic heart disease.
In conclusion, the past few decades of heart regeneration research
have been exciting and informative. Considerable progress has been
made to establish cell transplantation techniques with bone marrow-
derived cells and CDCs, and hPSC-derived cardiomyocytes have been
well established in preclinical studies as a promising cell type moving
forward. While many challenges lie ahead before successfully
regenerating the human heart, we are optimistic that theﬁeld ismoving
forward on a promising path.
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